Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck~  * Stage III or IV disease~    * No evidence of distant metastases~ * No salivary gland or paranasal sinus squamous cell carcinoma~* No disease with close proximity to a major vessel~* Measurable disease~* No known CNS or brain metastases~  * Patients with intracranial extension without cerebral involvement may be eligible~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy \> 12 weeks~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Bilirubin normal~* AST and ALT ≤ 2 times upper limit of normal~* PT normal~* Creatinine normal OR~* Creatinine clearance ≥ 60 mL/min~* Urine protein: creatinine ratio \< 1.0~* No bleeding diathesis or coagulopathy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs~* No pre-existing peripheral neuropathy ≥ grade 2~* No ongoing or active infection~* No serious non-healing wound, ulcer, or bone fracture~* No New York Heart Association class II-IV congestive heart failure~* No significant arrhythmias requiring medication~* No myocardial infarction within the past 6 months~* No stroke within the past 6 months~* No symptomatic coronary artery disease~* No second- or third-degree heart block or bundle branch block~* No unstable angina pectoris~* No hypertension (i.e., blood pressure ≥ 150/100 mm Hg)~* No other clinically significant heart disease~* No significant traumatic injury within the past 4 weeks~* No psychiatric illness or social situation that would preclude study compliance~* No HIV positivity~* No other malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix~* No other uncontrolled illness~* No poorly compliant patients~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy~* No prior investigational anticancer agents~* More than 4 weeks since prior major surgery~* More than 1 week since prior minor surgery, fine-needle aspiration, or core needle biopsy~* No concurrent major surgery except planned neck dissection~* No concurrent routine colony-stimulating factor therapy~* No other concurrent investigational agents~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bevacizumab with docetaxel and radiation therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).